NKTR Nektar Therapeutics

Price (delayed)

$3.97

Market cap

$739.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.67

Enterprise value

$813.75M

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. ...

Highlights
The debt has decreased by 5% YoY
The gross profit has declined by 25% year-on-year but it has increased by 2.1% since the previous quarter
The net income has declined by 15% year-on-year but it has grown by 6% since the previous quarter
Nektar Therapeutics's equity has decreased by 39% YoY and by 11% QoQ
Nektar Therapeutics's quick ratio has decreased by 25% from the previous quarter and by 23% YoY

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
186.27M
Market cap
$739.51M
Enterprise value
$813.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.22
Price to sales (P/S)
7.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.89
Earnings
Revenue
$103.08M
EBIT
-$449.13M
EBITDA
-$434.79M
Free cash flow
-$440.32M
Per share
EPS
-$2.67
Free cash flow per share
-$2.37
Book value per share
$3.26
Revenue per share
$0.55
TBVPS
$5.1
Balance sheet
Total assets
$1.02B
Total liabilities
$416.23M
Debt
$142.24M
Equity
$607.89M
Working capital
$628.17M
Liquidity
Debt to equity
0.23
Current ratio
6.97
Quick ratio
6.62
Net debt/EBITDA
-0.17
Margins
EBITDA margin
-421.8%
Gross margin
76.3%
Net margin
-476.6%
Operating margin
-439.7%
Efficiency
Return on assets
-41%
Return on equity
-65.6%
Return on invested capital
-41.7%
Return on capital employed
-48.9%
Return on sales
-435.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
-1.24%
1 week
3.39%
1 month
12.15%
1 year
-77.2%
YTD
-70.61%
QTD
-26.35%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$103.08M
Gross profit
$78.63M
Operating income
-$453.27M
Net income
-$491.26M
Gross margin
76.3%
Net margin
-476.6%
The net margin has decreased by 40% YoY but it has increased by 7% QoQ
The operating margin has contracted by 38% YoY
The gross profit has declined by 25% year-on-year but it has increased by 2.1% since the previous quarter
The revenue has contracted by 18% YoY

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
1.22
P/S
7.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.89
Nektar Therapeutics's EPS has decreased by 12% YoY but it has increased by 7% QoQ
The P/B is 98% below the 5-year quarterly average of 69.7 and 62% below the last 4 quarters average of 3.2
Nektar Therapeutics's equity has decreased by 39% YoY and by 11% QoQ
The stock's P/S is 70% less than its last 4 quarters average of 24.2 and 69% less than its 5-year quarterly average of 23.5
The revenue has contracted by 18% YoY

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's ROE has plunged by 72% YoY and by 6% from the previous quarter
NKTR's ROA is down by 46% YoY and by 2.2% from the previous quarter
The return on invested capital has declined by 45% year-on-year
Nektar Therapeutics's return on sales has decreased by 40% YoY but it has increased by 7% QoQ

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 146% more than its total liabilities
Nektar Therapeutics's total assets has decreased by 30% YoY and by 8% from the previous quarter
The company's current ratio fell by 25% QoQ and by 22% YoY
The debt is 77% lower than the equity
The debt to equity has soared by 53% YoY and by 10% QoQ
Nektar Therapeutics's equity has decreased by 39% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.